Background Transthyretin amyloidosis, also called ATTR amyloidosis, is associated with
accumulation of ATTR amyloid deposits in the heart and commonly manifests as progressive …

Transthyretin amyloid cardiomyopathy (ATTR-CM) has been traditionally considered a rare
and inexorably fatal condition. ATTR-CM now is an increasingly recognized cause of heart …

Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive and fatal condition that
requires early diagnosis, management, and specific treatment. The availability of new …

Importance The population prevalence of cardiac transthyretin amyloidosis (ATTR) caused
by pathogenic variation in theTTRgene (vATTR) is unknown. Objective To estimate the …

Tafamidis was associated with a reduction in cardiovascular hospitalizations and all-cause
mortality in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) in the ATTR-ACT …

Aims Recognition of transthyretin amyloid cardiomyopathy is increasing due to advances in
cardiac imaging and diagnostic strategies, but questions remain regarding disease …

New focused ultrasound spinal cord applications have emerged, particularly those
improving therapeutic agent delivery to the spinal cord via blood–spinal cord barrier …

Amyloidoses are a complex group of clinical diseases that result from progressive organ
dysfunction due to extracellular protein misfolding and deposition. The two most common …

Background Transthyretin cardiac amyloidosis (ATTR-CA) is increasingly recognized as a
treatable form of heart failure. Atrial fibrillation (AF) is common in patients with ATTR-CA …

Background Despite advances in imaging techniques, endomyocardial biopsy remains the
gold standard for confirming cardiac amyloidosis (CA) and defining the amyloid type …